Genta Incorporated (Genta), is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. Recently the news is that the company will run out of funds around June 2009. This of course has driven the stock to new low levels. The stock is trading for pennies (or even less) compared to 2006 levels of nearly three dollars.
The company appears to have several patents in the works and drugs in phase 3 testing. All in all the company appears to have a fairly bright future, but that future really depends on financing.
This stock is an EXTREME gamble and is not for an investor looking for a “safe cash deposit”.
This recent news just released shows that the company just might pull it off.
Genta Incorporated (GNTA) announced that the independent Data Monitoring Board (DMB) for AGENDA, a randomized Phase 3 trial of Genasense(R) in patients with advanced melanoma, has informed the Company that the study has passed its final futility analysis for progression-free survival (PFS). Accordingly, the Board has recommended that the study should continue to completion.

Coincident with this recommendation, Genta has submitted an “intent-to-file” notice via the centralized procedure to the European Medicines Agency (EMEA), along with a request for assignment of rapporteurs. Such notice is required prior to submission of a Marketing Authorization Application (MAA).


There is a very good chance this company will simply fold up, be broken up and sold, or simply close.
However, if they do enter into a financing arrangement with anyone, this one could go through the roof.
Invest in this one wisely and be prepared to lose it all.
However, this is a “fun one” that could turn your small gamble into a large return.
Remember we are making “guesses” and forward looking statements without facts.
Do not make any decisions without throughly applying common sense.

View admin's Profile      Subscribe via RSS